When will Beam Therapeutics submit a BLA for Risto-cel?
22.0 pts (24h)Health & MedicineOne-OffScience1mo
KalshiCheck availabilityKYC required2% feeVerified resolution dataFairly calibratedCurrent implied probability
before April 2027 93%Leader of 6 outcomes
Market quality
44 / 100
Low quality24h Volume
$1.2K
Liquidity
$19.6K
Medium liquiditySpread
84.0 pt
Wide spreadMarket data
Updated 13 minutes ago
Mar 24, 26, 2:00 PM UTCNov 1, 26, 5:00 AM UTC
Trends
Related Markets
Related questions for context, not a comparison of equivalent contracts.
FDA decision: Ivonescimab by Summit Therapeutics (in 2026)
KalshiFDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
KalshiWhen will Compass Pathways submit a NDA for COMP360 psilocybin?
KalshiWill we get AGI before 2029?
Manifold MarketsWill we get AGI before 2028?
Manifold MarketsWill we get room temperature superconductors before 2033?
Manifold MarketsRules
If Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA before Sep 1, 2026, then the market resolves to Yes.
- If Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA before Oct 1, 2026, then the market resolves to Yes.
- If Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA before Nov 1, 2026, then the market resolves to Yes.
- If Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA before Dec 1, 2026, then the market resolves to Yes.
- If Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA before Jan 1, 2027, then the market resolves to Yes.
- If Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA before Apr 1, 2027, then the market resolves to Yes.
Open markets
Health & Medicine
POLYMARKETHantavirus pandemic in 2026?
- No97%
- Yes3%
- Total Vol
- $18.1M
- 24h Vol
- $20.3K
POLYMARKETNew pandemic in 2026?
- No94.1%
- Yes5.9%
- Total Vol
- $1.1M
- 24h Vol
- $4.7K
KALSHIMedtronic cardiovascular growth in Q2
- Above 8%92%
- Above 9%81%
- Above 11.5%53%
+6 more outcomes
- Total Vol
- $3K
- 24h Vol
- $3K
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 4000+1.0pt98%
- Above 6000+2.0pt61%
+2 more outcomes
- Total Vol
- $1M
- 24h Vol
POLYMARKETMeasles cases in U.S. in 2026?
- ↑3.5k100%
- ↑500+0.1pt100%
- ↑1k+0.1pt100%
+9 more outcomes
- Total Vol
KALSHIPandemic in 2026?
- No95%
- Yes5%
- Total Vol
- $712.2K
- 24h Vol
- $1.4K
- Which countries will report an Ebola disease case before October?
- What will RFK say during RNC Midterm Convention?
- When will the FDA approve Intellia Therapeutics' lonvo-z?
- Will the FDA approve retatrutide?
- Measles cases in U.S. by September 30?
- Will WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- How many West Nile neuroinvasive disease cases will be reported among New York City residents in 2026?
- Will 3 mg THC beverages qualify as hemp under federal law?
- Heidi Overton confirmed as FDA Commissioner by which date?
Frequently asked questions
- What are the current odds for When will Beam Therapeutics submit a BLA for Risto-cel??
- Kalshi prices before April 2027 at 93% as of September 10, 2026.
- When does When will Beam Therapeutics submit a BLA for Risto-cel? resolve?
- When will Beam Therapeutics submit a BLA for Risto-cel? is scheduled to resolve on November 1, 2026.
- How is When will Beam Therapeutics submit a BLA for Risto-cel? settled?
- Kalshi settles this market as follows: If Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA before Sep 1, 2026, then the market resolves to Yes.